Next Article in Journal
Bullous Central Serous Chorioretinopathy: A Rare and Atypical Form of Central Serous Chorioretinopathy. A Systematic Review
Next Article in Special Issue
The Possible Contribution of P-Glycoprotein in the Protective Effect of Paeonol against Methotrexate-Induced Testicular Injury in Rats
Previous Article in Journal
Towards Better Delivery of Cannabidiol (CBD)
Previous Article in Special Issue
Entrapment of Citrus limon var. pompia Essential Oil or Pure Citral in Liposomes Tailored as Mouthwash for the Treatment of Oral Cavity Diseases
Review

Future of Chondroprotectors in the Treatment of Degenerative Processes of Connective Tissue

1
Institute of Living Systems, Immanuel Kant Baltic Federal University, A. Nevskogo Street 14, 236016 Kaliningrad, Russia
2
Department of Bionanotechnology, Kemerovo State University, Krasnaya Street 6, 650043 Kemerovo, Russia
3
Laboratory of Biocatalysis, Kemerovo State University, Krasnaya Street 6, 650043 Kemerovo, Russia
4
Natural Nutraceutical Biotesting Laboratory, Kemerovo State University, Krasnaya Street 6, 650043 Kemerovo, Russia
5
Department of General Mathematics and Informatics, Kemerovo State University, Krasnaya Street 6, 650043 Kemerovo, Russia
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(9), 220; https://doi.org/10.3390/ph13090220
Received: 14 July 2020 / Revised: 19 August 2020 / Accepted: 26 August 2020 / Published: 28 August 2020
Osteoarthritis is one of the most common diseases of the connective tissue of the elderly. It was found that most epidemiological studies used the Kellgren and Lawrence system for classification of osteoarthritis, which indicates one of the 5 degrees (0–4) of osteoarthritis in various joints according to the radiographic atlas. It has been proven that chondroprotectors are represented by the following active substances: chondroitin sulfate, glucosamine sulfate or hydrochloride, hyaluronic acid, glycosaminoglycans, extraction preparations from animal or plant raw materials. The sources of raw materials for the manufacture of combined chondroprotectors are known, methods for their preparation and use are described. The main drugs on the chondroprotective market are presented. The effectiveness of their use for the treatment of osteoarthritis has been proven. It was found that preparations containing chondroitin sulfate have anti-inflammatory activity, affecting mainly the cellular component of inflammation, stimulate the synthesis of hyaluronic acid and proteoglycans. Methods of treating osteoarthritis using cell therapy (the use of readily available, highly proliferative, and multipotent mesenchymal stromal cells) are presented. View Full-Text
Keywords: osteoarthritis; chondroprotectors; treatment; collagen; chondrocytes; hyaluronic acid osteoarthritis; chondroprotectors; treatment; collagen; chondrocytes; hyaluronic acid
Show Figures

Graphical abstract

MDPI and ACS Style

Sukhikh, S.; Babich, O.; Prosekov, A.; Patyukov, N.; Ivanova, S. Future of Chondroprotectors in the Treatment of Degenerative Processes of Connective Tissue. Pharmaceuticals 2020, 13, 220. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13090220

AMA Style

Sukhikh S, Babich O, Prosekov A, Patyukov N, Ivanova S. Future of Chondroprotectors in the Treatment of Degenerative Processes of Connective Tissue. Pharmaceuticals. 2020; 13(9):220. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13090220

Chicago/Turabian Style

Sukhikh, Stanislav, Olga Babich, Alexander Prosekov, Nikolai Patyukov, and Svetlana Ivanova. 2020. "Future of Chondroprotectors in the Treatment of Degenerative Processes of Connective Tissue" Pharmaceuticals 13, no. 9: 220. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13090220

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop